Full Press Release Details
Drug Application to FDA for KIT-302
TEL AVIV, Israel, July 31, 2017 /PRNewswire/
Kitov Pharmaceuticals Holdings Ltd.
(NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that it has submitted a New Drug Application
(NDA) to the U.S. Food and Drug Administration (FDA) for KIT-302, its lead drug candidate. KIT-302 is a patented combination of
celecoxib and amlodipine, and is intended to treat osteoarthritis pain and hypertension simultaneously.
The company expects that within 60
days the FDA will determine whether the NDA is complete and acceptable for filing.
"We are pleased with the dedicated,
professional work of our staff, investigators, and CROs. We look forward to working with FDA as it reviews the NDA," stated
J. Paul Waymack, M.D., Sc.D., Kitov's Chairman of the Board and Chief Medical Officer. "We are on track to meet our anticipated
Prescription Drug User Fee Act (PDUFA) dates with respect to FDA filing the NDA in the third quarter of 2017, and rendering a decision
on approval for marketing of KIT-302 during the second quarter of 2018."
Dr. Waymack added, "The data
in KIT-302's pivotal Phase III clinical trial were generated, collected, validated and analyzed by leading independent clinical
research organizations, service providers, as well as expert clinical investigators. The data demonstrated that the Phase III study
of KIT-302 met its primary endpoint with statistical significance of p=0.001."
About Kitov Pharmaceuticals
Kitov Pharmaceuticals
(NASDAQ: KTOV, TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial
expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development
and approval. Kitov's flagship combination drug, KIT-302, intended to treat osteoarthritis pain and hypertension simultaneously,
achieved the primary efficacy endpoint for its Phase III clinical trial. Kitov's newest drug, NT219, which is developed by its
majority owned subsidiary, TyrNovo Ltd., is a small molecule that presents a new concept in cancer therapy, and in combination
with various approved oncology drugs, demonstrated potent anti-tumor effects and increased survival in various cancer models.
By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver rapid
ROI and long-term potential to investors, while making a meaningful impact on people's lives. For more information on Kitov, the
content of which is not part of this press release, please visit http://www.kitovpharma.com.
Forward-Looking Statements and
Kitov's Safe Harbor Statement
in this press release are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend", "plan", "may",
"should", "could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue
reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect
our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,
involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may
cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include,
among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process
with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length,
progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any
changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory
approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration
or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and
regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products
once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence
on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend
issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail,
obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation,
and/or regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical
public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial
and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and
other factors that are discussed in our in our Annual Report on Form 20-F for the year ended December 31, 2016 and in our other
filings with the SEC, including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration
Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected
results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press
release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any
forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise,
except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to
the SEC, which are available on the SEC's website, http://www.sec.gov.
Chief Financial Officer
+972-3-9333121 ext. #105
LifeSci Advisors, LLC